Company intelligence / Profile preview

LysoTech

Seoul, Seoul, South Korealysotech.com ↗

Ownership: Private
Development stage: Other

Overview

LysoTech is a biotechnology company focused on developing novel therapeutics that target the autophagy-lysosomal pathway to treat metabolic, renal, and neurodegenerative diseases. The company's proprietary autophagy control platform is designed to activate Transcription Factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy, to restore cellular organelle function. Its lead candidate, MSL-7, is a small molecule autophagy enhancer being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), type 2 diabetes, chronic kidney disease (CKD), and dementia. LysoTech was acquired by Daelim in August 2024 to further advance its pipeline of organelle-rejuvenating therapies.

Therapeutic areas: NephrologyNeurologyEndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Korea Drug Development Fund (KDDF)

Beyond the preview

Go deeper on LysoTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LysoTech.